✦ LIBER ✦

Antitumor, endocrine, and metabolic effects of 16α-estradiol dipropionate in women with breast cancer

✍ Scribed by Elaine B. Feldman; Joseph N. Silverstein; Ramnath V. Nayak; Anne C. Carter

Publisher: John Wiley and Sons
Year: 1962
Tongue: English
Weight: 275 KB
Volume: 15
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(196209/10)15:5<1073::aid-cncr2820150525>3.0.co;2-s

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined endocrine effects of LHRH agoni

Combined endocrine effects of LHRH agonist (Zoladex®) and tamoxifen (Nolvadex®) therapy in premenopausal women with breast cancer

✍ Mr J. F. R. Robertson; K. J. Walker; R. I. Nicholson; R. W. Blamey 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 2 views

Abstract In premenopausal women with breast cancer, the use of the luteinizing hormone releasing hormone agonist, goserelin, results in the production of serum levels of oestradiol equivalent to those after surgical oöphorectomy or in postmenopausal women. The standard first line hormonal treatment

The effect of endocrine therapy with med

The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer

✍ M. J. Reed; A. Christodoulides; R. Koistinen; M. Seppälä; J. D. Teale; M. W. Ghi 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 413 KB 👁 2 views